6 research outputs found
Estudios efectivos de potencial para algunas nuevas moléculas híbridas para su actividad contra el cáncer de próstata
Objective: The present work aimed at developing novel hybrid molecules for targeting the prostate cancer. It is observed that two human shock proteins Hsp70 and Hsp90 are over-expressed in prostate cancer making them one of the important drug targets. We have designed and developed twelve new hybrid molecules 6a-j for targeting these proteins. Methods: The designed molecules were prepared following a four step reaction protocol and characterized on the basis of proton NMR and Mass spectrometry. These were subjected to in vitro studies by means of Oncotest and CCK-8 assays with two cell lines DU145 and 22Rv1. The selected molecules 6b and 6i were subjected to molecular docking and then for SPR based affinity assay. Results: Compounds 6b and 6i were found to be highly active anticancer compounds comparable to standard drug enzalutamide. They have significant IC50 and high dock score for the Hsp70 and Hsp90. These compounds are selective and have good binding affinity for the Hsp70 due to high Kd. Conclusion: Compound 6b and 6i can serve as lead molecules for the development of antiprostate cancer drugs with Hsp70 as target.Objetivo: El presente trabajo tuvo como objetivo desarrollar nuevas moléculas híbridas para atacar el cáncer de próstata. Se observa que dos proteínas de choque humano, Hsp70 y Hsp90, se sobreexpresan en el cáncer de próstata, lo que las convierte en uno de los objetivos farmacológicos importantes. Hemos diseñado y desarrollado doce nuevas moléculas híbridas 6a-j para dirigir estas proteínas. Métodos: Las moléculas diseñadas se prepararon siguiendo un protocolo de reacción de cuatro etapas y se caracterizaron sobre la base de RMN de protón y espectrometría de masas. Estos se sometieron a estudios in vitro por medio de ensayos Oncotest y CCK-8 con dos líneas celulares DU145 y 22Rv1. Las moléculas seleccionadas 6b y 6i se sometieron a acoplamiento molecular y luego a ensayo de afinidad basado en SPR. Resultados: Se descubrió que los Compuestos 6b y 6i son compuestos anticancerígenos muy activos comparables al fármaco estándar enzalutamida. Tienen un IC50 significativo y una puntuación alta para el muelle de Hsp70 y Hsp90. Estos compuestos son selectivos y tienen una buena afinidad de unión por la Hsp70 debido a la alta Kd. Conclusión: Los compuestos 6b y 6i pueden servir como moléculas principales para el desarrollo de fármacos antiprostáticos contra el cáncer con Hsp70 como objetivo
Estudios efectivos de potencial para algunas nuevas moléculas híbridas para su actividad contra el cáncer de próstata
Objective: The present work aimed at developing novel hybrid molecules for targeting the prostate
cancer. It is observed that two human shock proteins Hsp70 and Hsp90 are over-expressed in prostate
cancer making them one of the important drug targets. We have designed and developed twelve new
hybrid molecules 6a-j for targeting these proteins.
Methods: The designed molecules were prepared following a four step reaction protocol and characterized
on the basis of proton NMR and Mass spectrometry. These were subjected to in vitro studies by
means of Oncotest and CCK-8 assays with two cell lines DU145 and 22Rv1. The selected molecules 6b
and 6i were subjected to molecular docking and then for SPR based affinity assay.
Results: Compounds 6b and 6i were found to be highly active anticancer compounds comparable to
standard drug enzalutamide. They have significant IC50 and high dock score for the Hsp70 and Hsp90.
These compounds are selective and have good binding affinity for the Hsp70 due to high Kd.
Conclusion: Compound 6b and 6i can serve as lead molecules for the development of antiprostate cancer
drugs with Hsp70 as target.Objetivo: El presente trabajo tuvo como objetivo desarrollar nuevas moléculas híbridas para atacar el
cáncer de próstata. Se observa que dos proteínas de choque humano, Hsp70 y Hsp90, se sobreexpresan
en el cáncer de próstata, lo que las convierte en uno de los objetivos farmacológicos importantes. Hemos
diseñado y desarrollado doce nuevas moléculas híbridas 6a-j para dirigir estas proteínas.
Métodos: Las moléculas diseñadas se prepararon siguiendo un protocolo de reacción de cuatro etapas
y se caracterizaron sobre la base de RMN de protón y espectrometría de masas. Estos se sometieron a
estudios in vitro por medio de ensayos Oncotest y CCK-8 con dos líneas celulares DU145 y 22Rv1. Las
moléculas seleccionadas 6b y 6i se sometieron a acoplamiento molecular y luego a ensayo de afinidad
basado en SPR.
Resultados: Se descubrió que los Compuestos 6b y 6i son compuestos anticancerígenos muy activos
comparables al fármaco estándar enzalutamida. Tienen un IC50 significativo y una puntuación alta para
el muelle de Hsp70 y Hsp90. Estos compuestos son selectivos y tienen una buena afinidad de unión por
la Hsp70 debido a la alta Kd.
Conclusión: Los compuestos 6b y 6i pueden servir como moléculas principales para el desarrollo de
fármacos antiprostáticos contra el cáncer con Hsp70 como objetivo
Design, synthesis and evaluation of novel enzalutamide analogues as potential anticancer agents
The androgen receptor inhibitor, Enzalutamide, proved effective against castration resistance prostate cancer, has demonstrated clinical benefits and increased survival rate in men. However, AR mutation (F876L) converts Enzalutamide from antagonist to agonist indicating a rapid evolution of resistance. Hence, our goal is to overcome this resistance mechanism by designing and developing novel Enzalutamide analogues. We designed a dataset of Enzalutamide derivatives using Enzalutamide's shape and electrostatic features to match with pharmacophoric features essential for tight binding with the androgen receptor. Based on this design strategy ten novel derivatives were selected including 5,5-dimethyl-3-(6-substituted benzo[d]thia/oxazol-2-yl)-2-thioxo-1-(4-(trifluoromethyl)pyridin-2-yl)imidazolidin-4-one (6a-j) for synthesis. All the compounds were evaluated in-vitro on prostate cancer cell lines DU-145, LNCaP and PC3. Interestingly, two compounds 3-(6-hydroxybenzo[d]thiazol-2-yl)-5,5-dimethyl-2-thioxo-1-(4-(trifluoromethyl)pyridin-2-yl) imidazolidin-4-one (6c, IC50 – 18.26 to 20.31μM) and 3-(6-hydroxybenzo[d]oxazol-2-yl)-5,5-dimethyl -2-thioxo- 1- (4-(trifluoromethyl) pyridin-2-yl)imidazolidin-4-one (6h, IC50 – 18.26 to 20.31μM) were successful with promising in-vitro antiproliferative activity against prostate cancer cell lines. The binding mechanism of potential androgen receptor inhibitors was further studied by molecular docking, molecular dynamics simulations and MM-GBSA binding free energy calculations and found in agreement with the in vitro studies. It provided strong theoretical support to our hypothesis
Dataset of 2-(2-(4-aryloxybenzylidene) hydrazinyl) benzothiazole derivatives for GQSAR of antitubercular agents
Fragment based Quantitative structure activity relationship (QSAR) analysis on reported 25 2-(2-(4-aryloxybenzylidene) hydrazinyl) benzothiazole dataset as antitubercular agents were carried out. Molecules in the current dataset were fragmented into six fragments (R1, R2, R3, R4, R5, R6).Group based QSAR Models were derived using Multiple linear regression (MLR) analysis and selected on the basis of various statistical parameters. Dataset of benzothiazole reveled importance of presence of halogen atoms on is essential requirement. The generated models will provide structural requirements of benzothiazole derivatives which can be used to design and develop potent antitubercular derivatives
Breaking through resistance in mCRPC: Enzalutamide analogues as effective anticancer agents for enhanced male survival
To alleviate metastatic castration-resistant prostate cancer (mCRPC), enzalutamide, a non-steroidal antiandrogen, is employed. Following androgen deprivation therapy or anti-androgen treatment, compensatory mechanisms in prostate cancer have been identified, leading to increased expression and function of steroidal receptors. Comparative studies involving individuals with CRPC have demonstrated enzalutamide's superior efficacy compared to its predecessor, bicalutamide. Currently, there are four nonsteroidal antiandrogens approved by the US Food and Drug Administration, with two investigational medications undergoing clinical trials. Enzalutamide effectively slowed prostate cancer growth by preventing nuclear translocation and gene expression that are dependent on the AR, according to preclinical research. Its effectiveness in metastatic hormone-sensitive prostate cancer was supported by clinical trials like ARCHES, which also showed an improvement in radiographic progression-free survival with an acceptable safety profile. Resistance to enzalutamide can occur due to the F786L mutation. Recent research has shown that analogues of enzalutamide can overcome this resistance, enhancing anticancer activity and improving male survival rates. We will explore various enzalutamide analogues, including those with trifluoromethyl, trifluoromethoxy, diarylhydantoin, benzothiazole or benzoxazole, and 1-hydroxy-2,2,2-trifluoro-1-ethyl moieties, primarily used to address the resistance issue. Additionally, we will highlight the structural activity relationships of these analogues, which may enhance their antiproliferative effects and increase male survival rates. Notably, imidazolidine derivatives exhibit the most significant antiproliferative activity